Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for the period ended March 31, 2026.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for the period ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
Item 7.01 · Regulation FD Disclosure
- Presentation materials posted April 30, 2026 and furnished as Exhibit 99.2
- Updated corporate presentation furnished as Exhibit 99.3
- Investor-relevant operating details contained in the accompanying presentations rather than the 8-K narrative
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $317M, up 19% YoY; SUBLOCADE revenue $232M, up 32%, underscoring continued product concentration
- Adjusted EBITDA $164M, up 112% YoY; GAAP net income $89M, up from $47M, reflecting strong operating leverage
- FY2026 guidance raised to $1,215M–$1,285M revenue and $620M–$660M adjusted EBITDA
- $500M convertible notes at 0.625% due 2031 refinanced the $333M term loan, increasing long-term debt to $486M
- Repurchased 3,974,153 shares for $125M at $31.45 average, leaving $275M under the $400M program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.